---

title: "The NLRP3 inflammasome as a key pathway in the affective and chronic fatigue symptoms of Long COVID"
tags:
- âž• 2025-12-25
- ðŸ§ª Biomarker
created: '2025-09-08'
published: '2025-09-08'

---


<details>
<summary>Zhang et al. (2025)</summary>

- **Authors:** Yingqian Zhang, Hussein Kadhem Al-Hakeim, Hawraa Kadhem Al-Jassas, Michael Maes.
- **Institutes:** Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences; Department of Chemistry, Faculty of Sciences, University of Kufa, Iraq; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Kufa, Iraq; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria; Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria; Research and Innovation Program for the Development of MU PLOVDIV (SRIPD-MUP), Medical University of Plovdiv, Plovdiv, Bulgaria; Kyung Hee University, Seoul, South Korea.
- **Publisher:** medRxiv
- **Link:** [DOI](https://doi.org/10.1101/2025.09.07.25335261)

</details>


## Summary

This research provides a significant biological explanation for the persistent ME/CFS-like symptoms in Long COVID, linking their severity to sustained activation of the NLRP3 inflammasome pathway. It shows that the intensity of the initial infection, particularly the degree of oxygen deprivation, can trigger a long-lasting inflammatory state. Identifying the NLRP3 pathway as a key driver is crucial because it is a known "druggable target," meaning that existing or developing drugs could potentially be repurposed to treat Long COVID by calming this specific source of inflammation, offering a promising avenue for future therapeutic interventions.

## What was researched?

This study investigated whether activation of a specific part of the innate immune system, known as the NLRP3 inflammasome, is linked to the persistent neuropsychiatric and chronic fatigue symptoms (termed the "physio-affective phenome") experienced by patients with Long COVID.

## Why was it researched?

Previous research established that the severity of Long COVID symptoms is predicted by the intensity of the acute COVID-19 infection, particularly by high fever and low oxygen saturation. This suggested that the immune-inflammatory response system (IRS) plays a key role, but there was a lack of specific data confirming the involvement of the NLRP3 inflammasome pathway in the chronic phase of the illness.

## How was it researched?

This was a patient data analysis study involving 161 Long COVID patients, assessed 6 to 9 months after their acute infection. Patients were divided into two groups ("mild" vs. "severe") based on their peak body temperature and oxygen saturation levels during the initial illness. Researchers measured the serum levels of NLRP3 and related inflammatory biomarkers, including caspase-1, IL-1Î², and IL-18, to determine the level of inflammasome activation during the Long COVID phase.

## What has been found?

The study found that patients who had experienced a more severe acute COVID-19 infection had significantly higher levels of NLRP3 and its associated inflammatory markers months later. These elevated biomarker levels were strongly correlated with the overall severity of Long COVID symptoms, including chronic fatigue, depression, and anxiety. Furthermore, low oxygen saturation ($SpO_2$) during the acute infection was a significant predictor of increased NLRP3 inflammasome activity in the subsequent months.

## Discussion

The authors acknowledge two main limitations. First, as a case-control study, it can demonstrate strong associations but cannot definitively prove a causal link between NLRP3 activation and Long COVID symptoms. Second, the study was conducted on a specific population in Iraq, and the findings need to be replicated in other countries to ensure generalizability.

## Conclusion & Future Work

The authors conclude that activation of the NLRP3 inflammasome is strongly associated with the severity of Long COVID. The findings suggest that targeting this pathway could be a beneficial therapeutic strategy for both the acute and chronic phases of COVID-19. They note that novel drugs are already in development to specifically inhibit NLRP3 activation, with several potential inhibitors like MCC950 ðŸ’Š, Dapansutrile ðŸ’Š, Melatonin ðŸ’Š, Colchicine ðŸ’Š, and Baricitinib ðŸ’Š already in clinical trials.
